195A ME NEUTRAL II C719-35NHP

Foil Me Once…

Lewiston, ME, 04240 United States of America / 3 Appendix Page 2 of 3 The validity of this appendix depends on the validity of the main certificate.

Moving up the value chain, and expanding addressable market size by providing materials solutions in select and prioritized areas Copyright © . 2025 9 GROWING AT GROWING AT 1 Core grows above macro driven by share wins and faster business development in prioritized portfolios (growth vectors) CATALYZE THE CORE 2 Portfolios in high growth markets grow faster than core – building sizeable businesses of scale rapidly BUILD NEW PLATFORMS OF SCALE ► Prioritizing ► differently ► Creating “space” ► focused front-end and back-end structures Copyright © . 2025 10 Organic revenue growth with margin expansion LONG TERM FINANCIAL TARGETS +100 to +200bps above GDP Organic revenue growth Copyright © . 2025 11 Pathway to 20%+ adjusted EBITDA margins Operating leverage • Organic volume growth and SG&A efficiencies from prioritizing resources across the company 2 Mix improvement • Increased sales in higher margin growth platforms 3 Productivity • Manufacturing & sourcing efficiencies • Footprint optimization • Digital technologies Avient margin expansion Schematic illustration only Productivity +400bps margin expansion 20%+ Strategic objective 16.2% 2024 adjusted +2% +1% Operating leverage +1% Mix improvement Copyright © . 2025 12 Disciplined capital allocation PRIORITIZATION AND PHILOSHOPY Capex Expected annual spend between 3-5% of revenue to support investment in organic growth M&A De-emphasized in near term; complement organic growth strategy with M&A over time, as needed 2 Dividends Increasing each year with underlying earnings growth 3 Debt pay down Target net debt to adjusted EBITDA less than 2.5x 4 Share repurchases Opportunistic buy backs 5 Copyright © . 2025 13 Avient is a compelling investment thesis 2024 Results 15Copyright © . Three Months Ended December 31, 2024 2023 Reconciliation to Condensed Consolidated Statements of Income $ EPS(1) $ EPS(1) Net income from continuing operations attributable to Avient shareholders $ 48.3 $ 0.52 $ 27.8 $ 0.30 Special items, after-tax (18.0) (0.20) 5.4 0.06 Amortization expense, after-tax 14.8 0.17 15.0 0.16 Adjusted net income / EPS $ 45.1 $ 0.49 $ 48.2 $ 0.52 Year Ended December 31, 2024 2023 Reconciliation to Condensed Consolidated Statements of Income $ EPS(1) $ EPS(1) Net income from continuing operations attributable to Avient shareholders $ 169.5 $ 1.84 $ 75.8 $ 0.83 Special items, after-tax 15.9 0.17 79.3 0.86 Amortization expense, after-tax 59.5 0.65 61.5 0.67 Adjusted net income / EPS $ 244.9 $ 2.66 $ 216.6 $ 2.36 Three Months Ended Year Ended Reconciliation to EBITDA and Adjusted EBITDA: 2024 2023 2024 2023 Net income from continuing operations – GAAP $ 48.5 $ 27.6 $ 170.7 $ 76.3 Income tax expense (benefit) 14.8 (7.0) 54.1 11.0 Interest expense 25.5 26.8 105.6 115.3 Depreciation and amortization from continuing operations 45.4 44.2 179.7 188.8 EBITDA from continuing operations $ 134.2 $ 91.6 $ 510.1 $ 391.4 Special items, before tax (23.9) 22.4 20.1 114.6 Interest expense included in special items — (0.1) (2.3) (2.3) Depreciation and amortization included in special items (0.3) — (1.5) (1.9) Adjusted EBITDA $ 110.0 $ 113.9 $ 526.4 $ 501.8 Adjusted EBITDA as a percent of sales 14.7 % 15.8 % 16.2 % 16.0 % Three Months Ended Year Ended 2024 2023 2024 2023 Sales: Color, Additives and Inks $ 467.7 $ 459.4 $ 2,046.5 $ 2,007.4 Specialty Engineered Materials 279.7 259.8 1,196.8 1,138.2 Corporate (0.9) (0.2) (2.9) (2.8) Sales $ 746.5 $ 719.0 $ 3,240.4 $ 3,142.8 Gross margin: Color, Additives and Inks $ 152.6 $ 148.3 $ 681.1 $ 631.2 Specialty Engineered Materials 84.2 78.1 374.9 341.8 Corporate 22.7 (17.5) 0.7 (80.5) Gross margin $ 259.5 $ 208.9 $ 1,056.7 $ 892.5 Selling and administrative expense: Color, Additives and Inks $ 92.8 $ 86.5 $ 384.9 $ 371.3 Specialty Engineered Materials 49.6 48.7 207.7 199.3 Corporate 31.5 30.6 134.8 125.1 Selling and administrative expense $ 173.9 $ 165.8 $ 727.4 $ 695.7 Operating income: Color, Additives and Inks $ 59.8 $ 61.8 $ 296.2 $ 259.9 Specialty Engineered Materials 34.6 29.4 167.2 142.5 Corporate (8.8) (48.1) (134.1) (205.6) Operating income $ 85.6 $ 43.1 $ 329.3 $ 196.8 Depreciation and amortization: Color, Additives and Inks $ 21.9 $ 22.2 $ 87.5 $ 98.3 Specialty Engineered Materials 21.0 19.8 82.1 81.5 Corporate 2.5 2.2 10.1 9.0 Depreciation and amortization $ 45.4 $ 44.2 $ 179.7 $ 188.8 Earnings before interest, taxes, depreciation and amortization (EBITDA): Color, Additives and Inks $ 81.7 $ 84.0 $ 383.7 $ 358.2 Specialty Engineered Materials 55.6 49.2 249.3 224.0 Corporate (6.3) (45.9) (124.0) (196.6) Other income, net 3.2 4.3 1.1 5.8 EBITDA from continuing operations $ 134.2 $ 91.6 $ 510.1 $ 391.4 Special items, before tax (23.9) 22.4 20.1 114.6 Interest expense included in special items — (0.1) (2.3) (2.3) Depreciation and amortization included in special items (0.3) — (1.5) (1.9) Adjusted EBITDA $ 110.0 $ 113.9 $ 526.4 $ 501.8 2 Year Ended December 31, Adjusted Free Cash Flow Calculation 2024 2023 Cash provided by operating activities $ 256.8 $ 201.6 Taxes paid on gain on sale of business — 104.1 One-time payout associated with deferred compensation plans 20.8 — Adjusted cash provided by operating activities $ 277.6 $ 305.7 Capital expenditures (121.9) (119.4) Adjusted free cash flow $ 155.7 $ 186.3 Three Months Ended March 31, 2024 Reconciliation to Condensed Consolidated Statements of Income $ EPS(1) Net income from continuing operations attributable to Avient shareholders $ 49.4 $ 0.54 Special items, after-tax 5.5 0.06 Amortization expense, after-tax 14.9 0.16 Adjusted net income / EPS $ 69.8 $ 0.76 3 AVNT February Investor Presentation_2_25.pdf Avient Investor Presentation - February 2025_w_Non-GAAP.pdf Avient February 2025 Investor Presentation_w_non-GAAP.pdf Non-GAAP- IR Deck - AVNT-2024.12.31 2.06.25 12PM.pdf Attachment

Shiny, transparent, saturated hues are disrupted by a deep opaque tone, while a highly de-saturated lime provides balance to this complex palette. 

These more sustainable additions to the Mevopur portfolio are being featured at Pharmapack Europe 2022, being held 18 and 19 May in the Paris Expo Porte de Versailles.

The new MEVOPUR products are being introduced at Pharmapack Europe 2021, being held October 13-14 in the Paris Expo Porte de Versailles. 

Three Months Ended Three Months Ended Three Months Ended